CD274 and non-small cell lung carcinoma: Very recently, the KEYNOTE-021 study demonstrated clinical efficacy using Pembrolizumab plus chemotherapy in treatment-naive advanced NSCLC, regardless of Pembrolizumab dose or PD-L1 status [15].